PICK A TIME SLOT
₹ Price not available
Mangaluru
₹
You will receive an SMS with a verification code on this number.
Are you new to hospital ?
We have sent you an OTP on
Resend OTP
Did not receive OTP? You can request for another OTP. Click on Resend OTP
Go Back
Your appointment is
confirmed.
The details will be shared via Email & SMS
Note :Temporary visitor restriction, only one attendant is permitted with the patient. Your cooperation is solicited.
-
-
-
-
-
-
Publications
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- IADVL
- KDS
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Overview
Field of Expertise
Fellowship & Membership
Languages Spoken
Awards & Achievements
Talks & Publications
- IADVL
- KDS
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Fellowship & Membership
Overview
Field of Expertise
Languages Spoken
Awards & Achievements
Talks & Publications
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
- IADVL
- KDS
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Languages Spoken
Overview
Fellowship & Membership
Field of Expertise
Awards & Achievements
Talks & Publications
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- IADVL
- KDS
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
Field of Expertise
Fellowship & Membership
Languages Spoken
Awards & Achievements
Talks & Publications
Overview
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
- IADVL
- KDS
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
Awards & Achievements
Fellowship & Membership
Field of Expertise
Languages Spoken
Talks & Publications
Overview
- Baa AK, Rastogi S, Fernandes S et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023.
- B H, Canute Fernandes S, Rastogi S. VIT-0910: Need for Cautious Optimism? J Clin Oncol. 2022.
- Fernandes S, Wyawahare M. Utility of quick sepsis-related organ failure assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections. J Family Med Prim Care. 2020 Jul.
- Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Enterococcus species. Indian J Med Res. 2013 May.
- Poster presentation: “Phase 2 trial of regorafenib in advanced synovial sarcomas” at CTOS 2023, Dublin. • conducted a prospective study on prognostic scoring systems in sepsis as a part of the PG dissertation.
- Completed a study on the prognostic factors and outcomes of patients with alveolar soft part sarcomas (ASPS).
- Conducted a phase 2 trial on the efficacy of regorafenib in advanced synovial sarcomas"
Dr. Sanal Fernandes has an impressive academic background including an MBBS from KMC, Mangalore, MD (Medicine) from JIPMER, Puducherry and DM (Medical Oncology) from AIIMS, New Delhi.
He has been accredited with multiple awards and achievements during his academic journey including the best outgoing postgraduate during residency at JIPMER.
He brings with him proficiency and expertise in the field of medical oncology. His interests span across hematological malignancies to solid tumours with experience in the administration of chemotherapy, immunotherapy and targeted therapies.
Dr. Sanal is fluent in English, Hindi, Kannada, Tamil, and Konkani. This allows him to connect with patients from diverse backgrounds. He is committed to providing compassionate cure and advancing cancer treatment through his clinical expertise and dedication, to deliver the highest standards of care to his patients.
- IADVL
- KDS
- Acute and Chronic Leukemias
- Lymphomas
- Myeloproliferative Neoplasms
- Breast Cancer
- Lung and Thoracic Tumours
- GI Tumours (Colon, Rectum, Stomach, Hepatobiliary)
- Genitourinary and Gynaecological Malignancies
- Soft Tissue Sarcomas and Bone Tumours
- English
- Hindi
- Kannada
- Konkani
- Tamil
- Malayalam
- Best Outgoing Resident in Medicine, JIPMER (2019).
- ESMO Certification (2023).
- Participated in the ESMO: ADC development and therapeutic applications workshop held in Singapore in October 2024.
Talks & Publications
Overview
Fellowship & Membership
Field of Expertise
Languages Spoken
Awards & Achievements
Refund Policy
1) Up to 4 hrs of appointment time:
Rescheduling of doctor appointment can be done within a week from the date of appointment as per doctor / slot availability.
Cancellation can be done with full refund of the payment.
2) Up to 2 hrs of appointment time:
Rescheduling of doctor appointment can be done within a week from the date of appointment as per doctor / slot availability.
Cancellation of appointment and refund with a cancellation charge of Rs.100/-.
3) Less than 2 hrs of appointment time:
Rescheduling / cancellation of appointment cannot be done, payment non-refundable in this case. However, Units can have the discretion to refund / reschedule in case of exigencies.
Please note : While making the payment online, above mentioned payment terms and conditions should be agreed upon by customers, by clicking in a box ( I agree) and then proceed for payment.
PATIENT CONSENT FOR TELEMEDICINE / TELECONSULTATION
Telemedicine involves the use of electronic communications to enable Hospitals/health care centres to provide healthcare services at different locations through exchange of information and for the purpose of improving patient care. I, confirm that I have received the necessary information to sign this form and I agree to take part in a live telemedicine/teleconsultation session with Manipal Hospitals.
I understand that:
- Interactive audio/video connection, electronic information and communication technologies shall be used for providing me with a telemedicine/teleconsultation.
- In case the information obtained via teleconsultation is not sufficient to make a diagnosis, I may be required to go to Manipal Hospitals for in-person consultation.
- Though the telemedicine/teleconsultation is private, other individuals, medical and non-medical, may be present to facilitate the consultation and that they will take reasonable steps to maintain confidentiality of the information obtained.
- A limited visual examination will take place during the telemedicine/teleconsultation and that it cannot replace a full medical examination done physically at Manipal Hospitals.
- I have the right to withhold or withdraw my consent to the use of telemedicine/teleconsultation in the course of my care at any time, without affecting my right to future care or treatment. I may also revoke my consent orally or in writing at any time.
- I may be prescribed medicines for treatment or/and diagnostic tests to further evaluate my health condition. All prescription will be sent to my registered email/phone no. Manipal Hospitals will keep a record of the consultation & prescription in my medical record.
- The telemedicine/teleconsultation services are not in any way intended to be used in case of an emergency.
- There can be potential risks with this technology e.g information transmitted may not be sufficient to allow for appropriate medical decision, the video /audio may disconnect/stop in-between, security protocols could fail causing a breach of privacy of personal medical information.
- Any relevant medical information about me including details of my medical history, examinations, x-rays, tests, photographs or other images may be transmitted /shared by Manipal Hospitals with their staff, specialist, business partners for the purpose of record, communications, feedback, enquires, follow ups, analysis etc.
- Manipal Hospitals responsibility shall terminate upon conclusion of this teleconference.
- I hereby consent that in consideration for the telemedicine / teleconsultation services rendered to me, I agree to pay the relevant charges.
- I hereby release Manipal Hospitals, its personnel and any other person participating in my care from any and all liability which may arise from authorized use of such Video / E-Consultation, Videotapes, Digital recording films and Photographs. I have read this document and understand the risk of the telemedicine / teleconsultation.
- I hereby consent to participate in a telemedicine / teleconsultation under the terms & conditions described in this document.
